| Literature DB >> 30894787 |
Irene A Stafford1,2, Alexandra Berra1, Charles G Minard3, Virginia Fontenot2, Rachel H Kopkin2, Eliza Rodrigue2, Charles M Roitsch4, Martha W Rac1, James B Hill5.
Abstract
Objective: The aim of this retrospective review is to evaluate trends in the management of maternal and congenital syphilis (CS) in a tertiary care center in New Orleans, LA. Study Design: All cases of maternal and neonatal syphilis over a five year period at Touro Infirmary, New Orleans, LA, were identified using ICD-9/10 codes. Charts were reviewed for demographic and obstetrical variables, stage of syphilis at diagnosis, lab values, and treatment regimen. Newborn treatment and other outcomes were recorded.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30894787 PMCID: PMC6393911 DOI: 10.1155/2019/2613962
Source DB: PubMed Journal: Infect Dis Obstet Gynecol ISSN: 1064-7449
Maternal demographics and syphilis characteristics: N = 73.
| Age (years): | 25.2 ± 6.2 |
| Gravidity: | 2.9 ± 2.0 |
| Parity: | 2.5 ± 1.6 |
|
| |
| Race: | |
| (i) African American | 65 (90.3) |
| (ii) White | 3, (4.2) |
| (iii) Hispanic | 4, (5.6) |
| (iv) Other | 1, (1.4%) |
|
| |
| Complete Prenatal Care (>3 visits) | 65, (89.0) |
|
| |
| Number of Prenatal Visits: | 8.8 ± 4.3 |
|
| |
| Gestational Age at First Prenatal Visit (weeks): | 14.1 ± 7.6 |
|
| |
| Prior Preterm Birth: | 10, (13.7) |
|
| |
| Substance Abuse: | 14, (19.4) |
|
| |
|
| |
|
| |
| Stage of Syphilis | |
| Primary | 10, (13.7) |
| Secondary | 3, (4.1) |
| Early Latent | 1, (1.4) |
| Late Latent/unknown | 59, (80.1) |
|
| |
| Gestational Age at Diagnosis (Weeks): | 16.9 ± 10.6 |
|
| |
| Titer at Diagnosis, n = 70 | |
| 1:4 or less | 32, (45.7) |
| 1:8 to 1:32 | 28, (40% |
| 1:64 or greater | 10, (14.3) |
|
| |
| Year of Diagnosis | |
| 2013 | 6, (8.2) |
| 2014 | 10, (13.7) |
| 2015 | 13, (17.8) |
| 2016 | 18, (24.7) |
| 2017 | 26, (35.6) |
|
| |
| Health Department Notified of Syphilis Diagnosis/treatment confirmed | 1, (1.4) |
|
| |
| PCN allergic | 6, (8.2) |
| Desensitized | 6 (100%) |
|
| |
| Correct Penicillin Administration | 43, (58.9) |
| Primary | 5, (11.6) |
| Secondary | 2, (4.7) |
| Early Latent | 1, (2.3) |
| Late Latent or unknown | 35, (81.4) |
|
| |
| Incorrect treatment | 30, (41) |
| Primary | 3, (10.0) |
| Secondary | 1, (3.3) |
| Early Latent | 0 |
| Late Latent or unknown | 26, (86.6) |
Data are n, (%) or mean SD.
∗∗p value = .771 for difference in correct/incorrect treatment according to stage of disease.
Antepartum variables: N = 73 unless otherwise specified.
| Variable | Yes (%) |
|---|---|
| Cerclage | 1, (1.4) |
|
| |
| GDM or Pre-GDM | 1, (1.4) |
|
| |
| Chronic Hypertension | 4, (5.6) |
|
| |
| Thyroid Disease | 0, (0) |
|
| |
| Asthma | 9, (12.3) |
|
| |
| Hepatitis B | 1/72 (1.4) |
|
| |
| Hepatitis C | 0, (0) |
|
| |
| HIV | 1, (1.4) |
|
| |
|
| |
| Gonorrhea | 6, (8.2) |
|
| |
|
| |
| Chlamydia | 7, (9.6) |
|
| |
|
| |
| Antenatal Corticosteroid Administration | 2/70 (2.9) |
|
| |
| Fetus Interrogated Sonographically for Evidence of CS | 11/72 (15.3) |
|
| |
| Of those interrogated, Evidence of CS Present | 1/11 (9.1) |
|
| |
| Oligohydramnios | 2/70 (2.9) |
|
| |
| Intrauterine Growth Restriction | 6/71 (8.45) |
Data are n (%).
Neonatal variables: N = 73 unless otherwise specified.
| Birth weight (grams) | 3018 ± 569 |
|
| |
| Gender | |
| Female | 29/69, (42.0) |
| Male | 40/69, (58.0) |
|
| |
| 1 Minute Apgar(mode): | 9 |
|
| |
| 5 Minute Apgar(mode): | 9 |
|
| |
| Symptomatic at Birth: | 6, (8.2) |
|
| |
| VDRL/RPR Performed | 46, (63.0) |
|
| |
| Titer results ( n = 46) | |
| Nonreactive | 22, (47.8) |
| 1:1 | 4, (8.70) |
| 1:2 | 5, (10.9) |
| 1:4 | 5, (10.9) |
| 1:8 | 4, (8.70) |
| 1:16 | 3, (6.5) |
| 1:32 | 2, (4.4) |
| Note: One was “reactive” with no value. | |
|
| |
| NICU Admission | 17, (23.3) |
|
| |
| Average NICU Stay (days) | 10.7 ± .5 |
|
| |
| Diagnosed as highly likely to have congenital syphilis | 12, (16.4) |
|
| |
| Treated with extended PCN regimen when mother not adequately treated (n = 30) | 6, (20.0) |
|
| |
| Asymptomatic low risk newborn treated with single dose PCN (n = 61) | 16, (26.2) |
Data are n (%) or mean ± SD.
Neonatal signs and symptoms: N = 73.
| Variable | Yes |
|---|---|
| Abnormal Neuroimaging | 1, (1.4) |
|
| |
|
| |
| Abnormal Ophthalmic Exam | 2,(2.7) |
|
| |
| Jaundice | 6, (8.2) |
|
| |
| Non-Immune Hydrops | 0, (0) |
|
| |
| Rhinitis | 0, (0) |
|
| |
| Hepatosplenomegaly | 0, (0) |
|
| |
| Rash | 0, (0) |
|
| |
| Extremity Problems (pseudoparalysis) | 2, (2.7) |
|
| |
| Skeletal Survey Done | 7, (9.60) |
|
| |
| Blood Transfusion Required | 1, (1.4) |
|
| |
| Intraventricular Hemorrhage | 0, (0) |
|
| |
| Bronchopulmonary Dysplasia | 0, (0) |
|
| |
| Retinopathy of Prematurity | 0, (0) |
|
| |
| Necrotizing Enterocolitis | 1, (1.4) |
|
| |
| Aneuploidy | 0, (0) |
|
| |
| Supplemental Oxygen Requirement | 7, (9.6) |
|
| |
| Ventilator Support Required | 1, (1.4) |
|
| |
| Surfactant Administered | 1, (1.4) |
|
| |
| Sepsis Workup Performed | 25, (34.2) |
|
| |
|
| |
| Neonatal Anomaly | 9, (12.3) |
|
| |
| Lab Abnormalities | 9, (12.3) |
|
| |
| Abnormal Lumbar Puncture | 11, (15.1) |
|
| |
| Intrauterine fetal demise | 2, (2.7) |
Data are n (%).
| GA at Delivery (weeks): mean ± SD | 37.6 ± 3.57 |
| Variable | Yes |
|---|---|
| Spontaneous Vaginal Delivery | 42/70 (60.0) |
|
| |
| Operative Vaginal Delivery | 4/70 (5.7) |
|
| |
| Cesarean Delivery | 24/70 (34.3) |
|
| |
| Preterm Delivery | 13/69 (18.9) |
|
| |
| PPROM | 6/70 (8.6) |
|
| |
| Magnesium Administration | 3/70 (4.3) |
|
| |
| Chorioamnionitis | 5/70 (7.1) |
|
| |
| Intrauterine Fetal Demise | 2/70 (2.8) |
Data are n (%).